Friday, 03 Apr 2020

You are here

Hyperuricemia Increases Risk of Diabetes, Death and CV Disorders in Hypertensive Patients

While hyperuricemia is linked to gout and many of the elements that make up the metabolic syndrome, it's not so clear that hyperuricemia is an independant risk factor for hypertension, diabetes, cardiovascular outcomes, etc.

A systematic review and metanalysis has shown that hyperuricemia slightly raises the risk of cardiovascular diseases and diabetes in patients with established hypertension.

Analysis of 17 cohort studies revealed that hyperuricemia significantly correlated with cardiovascular diseases in hypertensive patients (hazard ratio [HR], 1.51; 95% confidence interval [CI], 1.13–2.03), all-cause mortality (HR, 1.12; 95%CI, 1.02–1.23), and diabetes (HR, 1.84; 95% CI, 1.02–3.30) but not with stroke (HR, 0.85; 95%CI, 0.57–1.27).

Hyperuricemia and risk of cardiovascular disease in hypertensive patients.

Hyperuricemia and risk of cardiovascular disease in hypertensive patients

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Interleukin-37 Targeting in Gout

The Annals of Rheumatic Disease reports that interleukin- 27 (IL-37) may play an important role in the pathogenesis of gout, paving the way for future therapy with recombinant IL-37 in gouty arthritis.

Activation of the inflammasome by monosodium urate crystals is thought to be paramount to the innate immune response that drives IL-1-mediated joint inflammation in gout.

Hyperuricemia Predisposes to Coronary Artery Disease in Men

There are numerous associations between hyperuricemia and cardiovascular disease (CVD). An analysis of the Swedish SCAPIS Pilot study shows that higher levels of serum urate (SU) are associated with an increase in coronary artery calcification score in men but not in women. SU is not associated with common carotid intima-media thickness and carotid plaque scores in either men or women.

Hypersensitivity Reactions and Gout Tx: Watch the Dose

Both allopurinol and febuxostat (Uloric) were associated with an increased risk of hypersensitivity reactions among new users of these urate-lowering therapies, a large U.S. study found.

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.